Precise MRI-Directed Sonic Ablation of Prostate Cancer

前列腺癌的精确 MRI 引导声波消融

基本信息

批准号：
7620908
负责人：
FRANK GRAHAM SOMMER
金额：
$ 53.93万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-01-13 至 2012-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7620908
关键词：
Ablation Acute Address Animal Model Appearance Arts Canis familiaris Chronic Deposition Development Devices Diffusion weighted imaging Disadvantaged Disease Environment Evaluation Focused Ultrasound Therapy Goals Heating Histologic Human Image Imaging Techniques In Vitro Lesion Magnetic Resonance Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Maps Modeling Monitor Organ Patient Schedules Patients Performance Phase Process Program Development Progress Reports Prostate Prostate Ablation Prostatectomy Prostatic Tissue Protocols documentation Puncture procedure Recruitment Activity Rectum Relative (related person)Research Research Ethics Committees Resected Safety Skin Skin Cancer Speed Structure Surface Surgical incisions System Techniques Technology Temperature Testing Thermal Ablation Therapy Time Tissues Ultrasonic Therapy Ultrasonics Ultrasonography Urethra Water Weight Work base cancer therapy design human subject in vivo men minimally invasive next generation patient safety public health relevance rectal treatment planning

项目摘要

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a minimally invasive, effective, and safe treatment for prostate cancer. Our specific aims are to 1) to optimize transurethral high intensity ultrasonic applicators for prostate ablation, 2) to rigorously evaluate the applicators in a canine model, including study of the accuracy of MR-guidance of ablation and elucidation of longer-term (6 weeks) fate of insonated prostate 3) to evaluate the relative advantages and differences of MR-guided transurethral high- intensity ultrasound compared to transrectal HIFU for targeted prostate ablation, 4) to evaluate the ability of our applicators to locally ablate selected prostate tissues under MRI guidance in human subjects with demonstrated patient safety. In the US, prostate cancer is the most common malignancy in men, excluding skin cancer. The techniques we are currently developing are designed for local control of prostate cancer (i.e., control of the primary process itself by ablation of prostatic tissues), and since up to 88% of prostate cancers are currently presenting as organ-confined disease, these therapies would thus be applicable to the majority of newly presenting cases. Focused ultrasound is a promising technique for the next generation of non- invasive cancer therapy systems. With this technology, ultrasound energy is focused at a point deep within the body to thermally ablate targeted tissue. This can be done with minimal heat deposition from the skin or cavity surface, without puncture or incision. The effort proposed here addresses the main technical challenges to using transurethral focused ultrasound therapy. The applicators will be developed to couple focused ultrasound treatment with Magnetic Resonance image guidance to allow precise targeting of the thermal energy to target tissues. Techniques to monitor heat deposition in targeted regions of the prostate gland, through accurate temperature mapping will be developed to insure that the entire target volume is being treated, and to ascertain that critical structures such as the rectum, the neurovascular bundles, and the urethra remain sufficiently cool to avoid damage. The new applicators and systems will be developed and evaluated both in vitro and in vivo. PUBLIC HEALTH RELEVANCE: We will develop and test an integrated system for the controlled ablation of prostate cancer using transurethral devices delivering high-intensity ultrasound to the prostate, directed by MRI thermal imaging, and incorporating rectal and urethral cooling

描述（由申请人提供）：该项目的长期目标是为前列腺癌开发一种微创，有效且安全的治疗。我们的具体目的是1）优化尿道高强度超声超声施用者以进行前列腺消融，2）在犬类模型中严格评估施用者，包括研究MR污染的准确性和阐明长期（6周）（6周）的精确度，以评估MRM MR的相对范围差异，以评估MRM MR的差异差异。针对靶向前列腺消融的经直肠HIFU，4）评估我们的施用者在人类受试者的MRI指导下局部消除所选的前列腺组织的能力，具有患者的安全性。在美国，前列腺癌是男性最常见的恶性肿瘤，不包括皮肤癌。我们目前正在开发的技术是为前列腺癌的局部控制而设计的（即通过消融前列腺组织来控制主要过程本身），并且由于目前多达88％的前列腺癌当前作为器官疾病呈现，因此这些疗法将适用于新出现病例的主要性。聚焦超声是下一代非侵入性癌症治疗系统的有前途技术。通过这项技术，超声能量集中在体内深处的一个渐进式靶向组织。这可以通过从皮肤或腔表面的最小热沉积进行，而无需穿刺或切口。此处提出的努力解决了使用尿道专注的超声疗法的主要技术挑战。将开发涂抹器将聚焦的超声处理与磁共振图像指南相结合，以允许将热能靶向靶向组织。将开发通过准确的温度映射来监测前列腺靶向区域中的热沉积的技术，以确保对整个目标体积进行处理，并确定临界结构（例如直肠，神经血管束，尿道）仍然充分冷却以避免损坏。新的施用者和系统将在体外和体内开发和评估。公共卫生相关性：我们将使用尿道尿道设备开发和测试用于控制前列腺癌的集成系统，该设备通过MRI热成像指导的前列腺高强度超声，并结合直肠和尿道冷却